Biologics for Psoriasis and Psoriatic Arthritis

Our aims

We aim to help people with psoriasis by:

• Providing information and advice
• Increasing public acceptance and understanding
• Collecting funds for and promoting research
• Representing the interests of members of a local and national level

Members of the Psoriasis Association receive:

• A quarterly magazine
• An invitation to the Annual Conference and ASM
• Information about local and national events
• Up to date information about treatments.

If you would like to join The Psoriasis Association, please contact us on 01604 251 620 or mail@psoriasis-association.org.uk or write to us at the address overleaf.

Make a donation

I would like to make a donation of £ ______ to the Psoriasis Association

I enclose a cheque

Please debit my card

Number

Start ___________ Expiry ___________ Issue ___________

Name _______________________ Address ________________________

_____________________________________________________________

Gift Aid

The Psoriasis Association will reclaim 25p of tax on every £1 donated. I am a UK taxpayer and understand that if I pay less Income Tax and/or Capital Gains tax than the amount of Gift Aid claimed on all my donations in that tax year it is my responsibility to pay any difference. I must notify the Psoriasis Association if I no longer pay sufficient tax to ensure you are using it correctly. If you would like more information, or a list of resources used in the production of this leaflet, please contact the Psoriasis Association.

Biologics availability

The knowledge and understanding of psoriasis and psoriatic arthritis is growing, and with this increased knowledge comes the ability to develop new treatments, or use the existing treatments more effectively. The following treatments have a marketing license at time of going to print, and have been assessed by the regulatory bodies accordingly:

Biologics Approved by the National Institute of Health and Care Excellence, for use in England and Wales:

<table>
<thead>
<tr>
<th>Biologic Name</th>
<th>For</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cosentyx (secukinumab)</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>Enbrel (etanercept)</td>
<td>Psoriasis and psoriatic arthritis</td>
</tr>
<tr>
<td>Humira (adalimumab)</td>
<td>Psoriasis and psoriatic arthritis</td>
</tr>
<tr>
<td>Remicade (infliximab)</td>
<td>Psoriasis and psoriatic arthritis</td>
</tr>
<tr>
<td>Simponi (golimumab)</td>
<td>Psoriatic arthritis</td>
</tr>
<tr>
<td>Stelara (ustekinumab)</td>
<td>Psoriasis and psoriatic arthritis</td>
</tr>
</tbody>
</table>

Biologics Approved by the Scottish Medicines Consortium, for use in Scotland:

<table>
<thead>
<tr>
<th>Biologic Name</th>
<th>For</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimzia (certolizumab pegol)</td>
<td>Psoriatic arthritis</td>
</tr>
<tr>
<td>Cosentyx (secukinumab)</td>
<td>Psoriasis and psoriatic arthritis</td>
</tr>
<tr>
<td>Enbrel (etanercept)</td>
<td>Psoriatic arthritis</td>
</tr>
<tr>
<td>Remicade (infliximab)</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>Simponi (golimumab)</td>
<td>Psoriatic arthritis</td>
</tr>
<tr>
<td>Stelara (ustekinumab)</td>
<td>Psoriasis and psoriatic arthritis</td>
</tr>
</tbody>
</table>

Biologics currently undergoing assessment at time of printing: Cimzia for psoriatic arthritis (NICE, decision expected to be published February 2017)

Cosentyx for psoriatic arthritis (NICE, decision expected to be published February 2017)

Humira, Enbrel and Stelara for use in children with severe psoriasis (NICE, decision expected to be published July 2017)

Taltz (ixekizumab) for psoriasis (NICE, decision expected to be published April 2017)

We rely on the generosity of people like you...

Each year the Psoriasis Association helps thousands of people whose lives have been affected by psoriasis via our websites, telephone and email helplines and by raising awareness amongst the general public, healthcare professionals and Members of Parliament.

We rely on your generosity to help us continue our vital work in supporting people, raising awareness and funding research.

How to contact us

The Psoriasis Association
Direx Cotes House 2 Queensbridge
Northampton NN4 7BF

Tel: 01604 251 620
Fax: 01604 251 621
Email: mail@psoriasis-association.org.uk

www.psoriasis-association.org.uk
www.psoteen.org.uk

A charity registered in England and Wales (251414) and in Scotland (SCO35988)

October 2016 (review 03/18)

The Psoriasis Association
Dick Coles House 2 Queensbridge
Northampton NN4 7BF

Tel: 01604 251 620
Fax: 01604 251 621
Email: mail@psoriasis-association.org.uk

www.psoriasis-association.org.uk
www.psoteen.org.uk
ciclosporin. The difference is that these treatments suppress the systemic medications (usually tablets) such as methotrexate and the immune system in some way. This is especially true of psoriasis causing chemicals released by them. They block the activation of the immune cells or block the psoriasis or psoriatic arthritis. In some cases biologics reduce symptoms to develop in the joints.

How do biologics work in psoriasis and psoriatic arthritis?

Biologics are designed to treat psoriasis and psoriatic arthritis by targeting the immune system. Some target specific types of immune cells found in psoriasis or to the joint damage associated with psoriatic arthritis or psoriatic arthritis. The relevant regulatory body (NICE, SMC, AWMSG) recommends that these TNF-alpha medications are also effective to different degrees in treating psoriatic arthritis and psoriasis. As well as medications that target TNF-alpha, there are biologic agents that target other proteins such as interleukin 12, 23, which are also involved in helping the immune system to fight off infections. Levels of IL-12 and IL-23 have been found to be higher than expected in people with psoriasis and psoriatic arthritis, and so biologics that block their activity may be useful for some people. Biologics that target other types of Interleukin are currently in final testing phases and may be available in the coming years.

What is biologics be offered?

A number of biologic medications were developed to treat rheumatoid arthritis and other conditions by blocking TNF-alpha lead to the rapid growth of skin tissue. Some biologic medications treat psoriasis by preventing the activation and/or movement of T cells, or by reducing the number of T cells in the body. The messages communicated by TNF-alpha lead to the rapid growth of skin tissue.